INTELGENX TECHNOLOGIES CORP., 10-K filed on 3/11/2014
Annual Report
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2013
Mar. 8, 2014
Jun. 30, 2013
Document Type
10-K 
 
 
Amendment Flag
false 
 
 
Document Period End Date
Dec. 31, 2013 
 
 
Trading Symbol
igxt 
 
 
Entity Registrant Name
IntelGenx Technologies Corp. 
 
 
Entity Central Index Key
0001098880 
 
 
Current Fiscal Year End Date
--12-31 
 
 
Entity Filer Category
Smaller Reporting Company 
 
 
Entity Common Stock, Shares Outstanding
 
62,600,656 
 
Entity Current Reporting Status
Yes 
 
 
Entity Voluntary Filers
No 
 
 
Entity Well Known Seasoned Issuer
No 
 
 
Entity Public Float
 
 
$ 28,352,182 
Document Fiscal Year Focus
2013 
 
 
Document Fiscal Period Focus
FY 
 
 
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current
 
 
Cash and cash equivalents
$ 5,005 
$ 2,059 
Accounts receivable
144 
1,282 
Prepaid expenses
133 
102 
Investment tax credits receivable
268 
213 
Total Current Assets
5,550 
3,656 
Leasehold Improvements and Equipment
588 
387 
Intangible Assets
79 
116 
Total Assets
6,217 
4,159 
Current
 
 
Accounts payable and accrued liabilities
593 
1,058 
Deferred license revenue
308 
308 
Total Current Liabilities
901 
1,366 
Deferred License Revenue, non-current portion
308 
615 
Total Liabilities
1,209 
1,981 
Commitments
   
   
Shareholders' Equity
 
 
Capital Stock
Additional Paid-in-Capital
20,934 
16,342 
Accumulated Deficit
(16,102)
(14,463)
Accumulated Other Comprehensive Income
175 
299 
Total Shareholders' Equity
5,008 
2,178 
Total Liabilities and Stockholders Equity
$ 6,217 
$ 4,159 
Consolidated Statement of Shareholders' Equity (USD $)
In Thousands, except Share data
Capital Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Total
Beginning Balance at Dec. 31, 2011
$ 0 
$ 15,918 
$ (12,213)
$ 199 
$ 3,904 
Beginning Balance (Shares) at Dec. 31, 2011
48,895,028 
 
 
 
 
Foreign currency translation adjustment
 
 
 
100 
100 
Warrants exercised
 
233 
 
 
233 
Warrants exercised (Shares)
726,080 
 
 
 
 
Agents warrants exercised
 
104 
 
 
104 
Agents warrants exercised (Shares)
219,313 
 
 
 
 
Options exercised
 
28 
 
 
28 
Options exercised (Shares)
50,000 
 
 
 
 
Stock-based compensation
 
59 
 
 
59 
Net loss for the period
 
 
(2,250)
 
(2,250)
Ending Balance at Dec. 31, 2012
16,342 
(14,463)
299 
2,178 
Ending Balance (Shares) at Dec. 31, 2012
49,890,421 
 
 
 
 
Foreign currency translation adjustment
 
 
 
(124)
(124)
Issue of common stock, net of transaction costs of $387
 
1,808 
 
 
1,808 
Issue of common stock, net of transaction costs of $387 (Shares)
7,920,346 
 
 
 
 
Warrants issued, net of transaction costs of $230
 
1,075 
 
 
1,075 
Agents' Warrants
 
100 
 
 
100 
Warrants exercised
1,464 
 
 
1,465 
Warrants exercised (Shares)
3,098,500 
 
 
 
 
Options exercised
 
31 
 
 
31 
Options exercised (Shares)
75,000 
 
 
 
 
Stock-based compensation
 
114 
 
 
114 
Net loss for the period
 
 
(1,639)
 
(1,639)
Ending Balance at Dec. 31, 2013
$ 1 
$ 20,934 
$ (16,102)
$ 175 
$ 5,008 
Ending Balance (Shares) at Dec. 31, 2013
60,984,267 
 
 
 
 
Consolidated Statements of Comprehensive Loss (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Revenues
 
 
Royalties
$ 188 
$ 0 
License and other revenue
760 
1,198 
Total Revenues
948 
1,198 
Expenses
 
 
Research and development expense
561 
1,723 
Selling, general and administrative expense
1,954 
1,689 
Depreciation of tangible assets
34 
37 
Amortization of intangible assets
38 
Total Costs and Expenses
2,587 
3,458 
Loss from Operations
(1,639)
(2,260)
Other Income
 
 
Interest and other income
10 
Total Other Income
10 
Loss Before Income Taxes
(1,639)
(2,250)
Income taxes
Net Loss
(1,639)
(2,250)
Other Comprehensive Income (Loss)
 
 
Foreign currency translation adjustment
(124)
100 
Comprehensive Loss
$ (1,763)
$ (2,150)
Basic and Diluted Weighted Average Number of Shares Outstanding
54,023,739 
49,637,908 
Basic and Diluted Loss Per Common Share
$ (0.03)
$ (0.04)
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Funds Provided (Used) - Operating Activities
 
 
Net loss
$ (1,639)
$ (2,250)
Amortization and depreciation
72 
46 
Stock-based compensation
114 
59 
Total Adjustments
(1,453)
(2,145)
Changes in assets and liabilities
 
 
Accounts receivable
1,138 
(1,019)
Prepaid and other assets
(31)
(34)
Other receivables
(55)
247 
Accounts payable and other accrued liabilities
(465)
390 
Deferred revenue
(307)
923 
Net change in assets and liabilities
280 
507 
Net cash used by operating activities
(1,173)
(1,638)
Financing Activities
 
 
Issuance of common stock and warrants
3,500 
Proceeds from exercise of warrants, agents' warrants and stock options
1,496 
365 
Transaction costs
(517)
Net cash provided by financing activities
4,479 
365 
Investing Activities
 
 
Additions to leasehold improvements and equipment
(266)
(270)
Net Cash used in investing activities
(266)
(270)
Increase (Decrease) in Cash and Cash Equivalents
3,040 
(1,543)
Effect of Foreign Exchange on Cash and Cash Equivalents
(94)
97 
Cash and Cash Equivalents
 
 
Beginning of Year
2,059 
3,505 
End of Year
$ 5,005 
$ 2,059 
Basis of Presentation
Basis of Presentation [Text Block]
1.

Basis of Presentation

   
 

IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

   
 

The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

   
 

The financial statements are expressed in U.S. funds.

Nature of Business
Nature of Business [Text Block]
2.

Nature of Business

   
 

The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies.

   
 

Technologies

   
 

The Company has developed three proprietary delivery platforms; including an immediate release oral film “ VersaFilm™ ”, a mucoadhesive tablet “ AdVersa™ ” and a multilayer controlled release tablet “ VersaTab™ ”.

   
 

The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds.

   
 

Product Pipeline

   
 

IntelGenx’ product pipeline currently consists of 12 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 5 utilize the VersaFilm™ technology, 4 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology. In accordance with contractual commitments and for reasons of confidentiality, the Company is unable to disclose either the indicated treatment or the delivery platform behind two of the products under development.

   
 

Approved and Commercialized Products

   
 

The Company’s first FDA-approved product, Forfivo XL®, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL® is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in Wellbutrin XL®.

Adoption of New Accounting Standards
Adoption of New Accounting Standards [Text Block]
3.

Adoption of New Accounting Standards

   
 

In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011-11. ASU 2011-11 and ASU 2013-01 are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

   
 

In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011-05 and 2011-12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies [Text Block]
4.

Summary of Significant Accounting Policies


 

Revenue Recognition

   
 

The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.

   
 

IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.

   
 

In August 2010, the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $800 thousand, of which $200 thousand was received by the Company in 2013 upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration. RedHill is required to make additional milestone payments of $500 thousand upon receipt of FDA marketing approval for the product, together with royalties and / or a share of profits upon commercialization.

   
 

In December 2011, the Company entered into a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par"), a US company, for a generic formulation of buprenorphine and naloxone Sublingual Film, utilizing the Company’s VersaFilm™ technology. The reference listed drug is Suboxone® (buprenorphine and naloxone) Sublingual Film and is indicated for the maintenance treatment of opioid dependence. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $500 thousand, of which $250 thousand was received by the Company in 2013 following successful completion of the pivotal bioequivalence study. The agreement provides for additional, undisclosed, milestone payments, together with a share of profits upon commercialization.

   
 

In February 2012, the Company entered into a license agreement with Edgemont Pharmaceuticals LLC (“Edgemont”), a US company, for the commercialization Forfivo XL®™ in the United States. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $2 million, and will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $26.5 million.


 

Product Sales:

   
 

The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $171 thousand in 2013.

   
 

Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $308 thousand in 2013 and has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.


 

Use of Estimates

   
 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.

   
 

Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.


 

Cash and Cash Equivalents

   
 

Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.


 

Accounts Receivable

   
 

The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2013 accounts receivable (2012 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.


 

Investment Tax Credits

   
 

Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.


 

Leasehold Improvements and Equipment

   
 

Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:


  On the declining balance method -  
     
         Laboratory and office equipment 20%
         Computer equipment 30%
     
  On the straight-line method -  
     
         Leasehold improvements over the lease term
         Manufacturing equipment 5 – 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

Intangible Assets

Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.

Impairment of Long-lived Assets

Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.

 

Foreign Currency Translation

   
 

The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:

Assets and liabilities - at exchange rates in effect at the balance sheet date;

Revenue and expenses - at average exchange rates prevailing during the year;

Equity - at historical rates.

Gains and losses arising from foreign currency translation are included in other comprehensive income.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Unrecognized Tax Benefits

The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.

  Share-Based Payments
   
 

The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.

   
 

The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.


 

Loss Per Share

   
 

Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.


 

Fair Value Measurements

   
 

ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:


  Level 1: Quoted market prices in active markets for identical assets or liabilities.
  Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
  Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2013.

Fair Value of Financial Instruments

The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.

Recent Accounting Pronouncements

In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

 

In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

   
 

In April 2013, the FASB issued Update No. 2013-07, “Presentation of Financial Statements – Liquidation Basis of Accounting”. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entitles should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.

   
 

In July 2013, the FASB issued Update No. 2013-11, “Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption and retrospective application is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.

Leasehold Improvements and Equipment
Leasehold Improvements and Equipment [Text Block]
5.

Leasehold Improvements and Equipment


                  2013     2012  
  In US$ thousands         Accumulated     Net Carrying     Net Carrying  
      Cost     Depreciation     Amount     Amount  
                           
  Manufacturing equipment $ 446   $ 0   $ 446   $ 225  
  Laboratory and office equipment   398     277     121     153  
  Computer equipment   46     35     11     9  
  Leasehold improvements - current premises   58     58     0     0  
  Leasehold improvements - future premises   10     0     10     0  
                           
    $ 958   $ 370   $ 588   $ 387  

 

As of December 31, 2013 no depreciation has been recorded on manufacturing equipment as the equipment is not, to date, being utilized by the Company.

   
 

Leasehold improvements carried out on our current premises have been fully depreciated. IntelGenx has invested approximately $10 thousand related to leasehold improvement activities for new premises that the Company intends to occupy later in 2014. No depreciation for this asset has been recorded as the premises are not, to date, being utilized by the Company.

Intangible Assets
Intangible Assets [Text Block]
6.

Intangible Assets

   
 

As of December 31, 2013 NDA acquisition costs of $79 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012.

Deferred License Revenue
Deferred License Revenue [Text Block]
7.

Deferred License Revenue

   
 

Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

   
 

Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.

Commitments
Commitments [Text Block]
8.

Commitments

   
 

The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410 - 6420 Abrams. In the first half of 2014, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 16,000 of rentable square feet. The term of the amended lease will be 10 years following relocation, which is expected to commence in the second half of 2014 upon completion of certain leasehold improvements.

   
 

As of December 31, 2013 future minimum payments under operating leases for facilities for the next 6 months are approximately $15 thousand.

   
 

On October 1, 2009, the Company signed an agreement with Little Gem Life Science Partners for investor relation services in the USA. Under the terms of the agreement, the Company was required to pay $4.5 thousand per month to Little Gem Life Science Partners. The Company renegotiated the agreement in May 2012 and reduced payments to $2.5 thousand per month. The agreement automatically renews unless specifically terminated.

   
 

On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL®, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL® in October 2012, the Company is required, after recovering an aggregate $200 thousand for management fees previously paid, to pay its former development partner 10% of net sales royalties received under the commercialization agreement that was executed with Edgemont Pharmaceuticals in February 2012. As of December 31, 2013 the Company has recovered approximately $147 thousand of said management fees.

Capital Stock
Capital Stock [Text Block]
9.

Capital Stock


      2013     2011  
  Authorized -            
               
  100,000,000 common shares of $0.00001 par value            
    20,000,000 preferred shares of $0.00001 par value            
               
  Issued -            
    60,984,267 (December 31, 2012 - 49,890,421) common shares $ 610   $ 499  

On December 16, 2013, as part of a registered public offering, the Company issued approximately 7.9 million shares of common stock at $0.4419 per share, and five-year warrants to purchase up to approximately 7.9 million shares of common stock, for aggregate gross proceeds of approximately US$3.5 million. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 60 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $1,808 thousand. (See note 10 for the portion allocated to the warrants).

The Company paid an agent cash commissions in the amount of approximately $210 thousand, representing 6% of the aggregate gross proceeds received by the Company, plus expenses in the amount of approximately $35 thousand, and issued warrants to the agent to purchase 475,221 shares of common stock, representing 6% of the amount of shares sold in the public offering. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 48 months after the date of issuance.

In addition, the Company paid approximately $272 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values.

In the year ended December 31, 2013 a total of 75,000 (2012 – 50,000) stock options were exercised for 75,000 (2012 – 50,000) common shares having a par value of $0 thousand (2012 - $Nil) in aggregate, for cash consideration of $31 thousand ($28 thousand), resulting in an increase in additional paid-in capital of $31 thousand (2012 – $28 thousand).

During the year ended December 31, 2013 no agents’ warrants were exercised. During the year ended December 31, 2012 a total of 219,313 agents’ warrants were exercised for 219,313 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand, resulting in an increase in additional paid-in capital of approximately $104 thousand.

 

Also in the year ended December 31, 2013 a total of 3,098,500 warrants were exercised for 3,098,500 common shares having a par value of $1 thousand in aggregate, for cash consideration of approximately $1,465 thousand, resulting in an increase in additional paid-in capital of approximately $1,464 thousand. In the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

Income Tax
Income Tax [Text Block]
11.

Income Taxes

   
 

Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows:


      2013     2012  
  Statutory income taxes $ (442 ) $ (605 )
  Net operating losses for which no tax benefits have been recorded   278     368  
  Excess of depreciation over capital cost allowance   11     3  
  Non-deductible expenses   56     18  
  Undeducted research and development expenses   142     273  
  Investment tax credit   (45 )   (57 )
               
    $ -   $   -  

The major components of the deferred tax assets classified by the source of temporary differences are as follows:

      2013     2012  
  Leasehold improvements and equipment $ 14   $ 13  
  Net operating losses carryforward   2,407     2,278  
  Undeducted research and development expenses   1,283     1,301  
  Non-refundable tax credits carryforward   1,098     914  
               
      4,802     4,506  
  Valuation allowance   (4,802 )   (4,506 )
    $ -   $   -  

The valuation allowance at December 31, 2012 was $4,506 thousand. The net change in the valuation allowance during the period ended December 31, 2013, was an increase of $296 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2013.

 

There were Canadian and provincial net operating losses of approximately $8,874 thousand (2012 - $8,390 thousand) and $9,040 thousand (2012 - $8,566 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2033. A portion of the net operating losses may expire before they can be utilized.

   
 

As at December 31, 2013, the Company had non-refundable tax credits of $1,098 thousand (2012 - $914 thousand) of which $22 thousand is expiring in 2017, $212 thousand is expiring in 2018, $186 thousand is expiring in 2019, $158 thousand is expiring in 2020, $169 thousand is expiring in 2021, $232 thousand is expiring in 2022 and $119 thousand is expiring in 2023 and undeducted research and development expenses of $4,354 thousand (2012 - $4,464 thousand) with no expiration date.

   
 

The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.

   
 

Unrecognized Tax Benefits

   
 

The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.

   
 

Tax Years and Examination

   
 

The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2013:


Tax Jurisdictions   Tax Years
Federal - Canada   2011 and onward
Provincial - Quebec   2011 and onward
Federal - USA   2011 and onward
Statement of Cash Flows Information
Statement of Cash Flows Information [Text Block]
12.

Statement of Cash Flows Information


  In US$ thousands   2013     2012  
               
  Additional Cash Flow Information:            
               
  Interest paid $ 5   $ 3  
Related Party Transactions
Related Party Transactions [Text Block]
13.

Related Party Transactions

   
 

Included in management salaries are $10 thousand (2012 - $6 thousand) for options granted to the Chief Executive Officer, $39 thousand (2012 - $Nil thousand) for options granted to the Chief Operating Officer, and $29 thousand (2012 - $6 thousand) for options granted to the Chief Financial Officer under the 2006 Stock Option Plan and $10 thousand (2012 - $23 thousand) for options granted to non-employee directors.

   
 

Included in general and administrative expenses are director fees of $80 thousand (2012 - $114 thousand) comprising an annual stipend and for attendance at board meetings and audit committee meetings.

   
 

The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

Basic and Diluted Loss Per Common Share
Basic and Diluted Loss Per Common Share [Text Block]
14.

Basic and Diluted Loss Per Common Share

   
 

Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Subsequent Events
Subsequent Events [Text Block]
15.

Subsequent Events

   
 

On January 13, 2014 the Company announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. for two new products utilizing IntelGenx' proprietary oral drug delivery platforms. Under the terms of the agreement, Par has obtained certain exclusive rights to market and sell IntelGenx' products in the USA. In exchange IntelGenx will receive upfront and milestone payments, together with a share of the profits upon commercialization. In accordance with confidentiality clauses contained in the agreement, the specifics of the product descriptions, platform technologies and financial terms were not disclosed.

   
 

Subsequent to the year ended December 31, 2013 an aggregate of 1,616,388 warrants were exercised for 1,616,388 common shares having a par value of $0 thousand for cash consideration of approximately $1 million, resulting in an increase in additional paid-in capital of approximately $1 million.

Summary of Significant Accounting Policies (Policies)
 

Revenue Recognition

   
 

The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.

   
 

IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.

   
 

Product Sales:

   
 

The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $171 thousand in 2013.

   
 

Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $308 thousand in 2013 and has a deferred revenue balance of $616 thousand at December 31, 2013 that has not been recognized as revenue.

 

Use of Estimates

   
 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.

   
 

Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

 

Cash and Cash Equivalents

   
 

Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.

 

Accounts Receivable

   
 

The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2013 accounts receivable (2012 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.

 

Investment Tax Credits

   
 

Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.

 

Leasehold Improvements and Equipment

   
 

Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:


  On the declining balance method -  
     
         Laboratory and office equipment 20%
         Computer equipment 30%
     
  On the straight-line method -  
     
         Leasehold improvements over the lease term
         Manufacturing equipment 5 – 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

Intangible Assets

Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.

Impairment of Long-lived Assets

Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.

 

Foreign Currency Translation

   
 

The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:

Assets and liabilities - at exchange rates in effect at the balance sheet date;

Revenue and expenses - at average exchange rates prevailing during the year;

Equity - at historical rates.

Gains and losses arising from foreign currency translation are included in other comprehensive income.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Unrecognized Tax Benefits

The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.

  Share-Based Payments
   
 

The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.

   
 

The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.

 

Loss Per Share

   
 

Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.

 

Fair Value Measurements

   
 

ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:


  Level 1: Quoted market prices in active markets for identical assets or liabilities.
  Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
  Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2013.

Fair Value of Financial Instruments

The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.

Recent Accounting Pronouncements

In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

Summary of Significant Accounting Policies (Tables)
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]
  On the declining balance method -  
     
         Laboratory and office equipment 20%
         Computer equipment 30%
     
  On the straight-line method -  
     
         Leasehold improvements over the lease term
         Manufacturing equipment 5 – 10 years
Leasehold Improvements and Equipment (Tables)
Schedule of Leasehold Improvements and Equipment [Table Text Block]
                  2013     2012  
  In US$ thousands         Accumulated     Net Carrying     Net Carrying  
      Cost     Depreciation     Amount     Amount  
                           
  Manufacturing equipment $ 446   $ 0   $ 446   $ 225  
  Laboratory and office equipment   398     277     121     153  
  Computer equipment   46     35     11     9  
  Leasehold improvements - current premises   58     58     0     0  
  Leasehold improvements - future premises   10     0     10     0  
                           
    $ 958   $ 370   $ 588   $ 387  
Capital Stock (Tables)
Schedule of Stock by Class [Table Text Block]
      2013     2011  
  Authorized -            
               
  100,000,000 common shares of $0.00001 par value            
    20,000,000 preferred shares of $0.00001 par value            
               
  Issued -            
    60,984,267 (December 31, 2012 - 49,890,421) common shares $ 610   $ 499  
Income Tax (Tables)
      2013     2012  
  Statutory income taxes $ (442 ) $ (605 )
  Net operating losses for which no tax benefits have been recorded   278     368  
  Excess of depreciation over capital cost allowance   11     3  
  Non-deductible expenses   56     18  
  Undeducted research and development expenses   142     273  
  Investment tax credit   (45 )   (57 )
               
    $ -   $   -  
      2013     2012  
  Leasehold improvements and equipment $ 14   $ 13  
  Net operating losses carryforward   2,407     2,278  
  Undeducted research and development expenses   1,283     1,301  
  Non-refundable tax credits carryforward   1,098     914  
               
      4,802     4,506  
  Valuation allowance   (4,802 )   (4,506 )
    $ -   $   -  
Statement of Cash Flows Information (Tables)
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
  In US$ thousands   2013     2012  
               
  Additional Cash Flow Information:            
               
  Interest paid $ 5   $ 3  
Nature of Business (Narrative) (Details)
12 Months Ended
Dec. 31, 2013
Nature Of Business 1
Nature Of Business 2
Summary of Significant Accounting Policies (Narrative) (Details) (USD $)
12 Months Ended
Dec. 31, 2013
D
Summary Of Significant Accounting Policies 1
45 
Summary Of Significant Accounting Policies 2
$ 800,000 
Summary Of Significant Accounting Policies 3
200,000 
Summary Of Significant Accounting Policies 4
500,000 
Summary Of Significant Accounting Policies 5
500,000 
Summary Of Significant Accounting Policies 6
250,000 
Summary Of Significant Accounting Policies 7
2,000,000 
Summary Of Significant Accounting Policies 8
26,500,000 
Summary Of Significant Accounting Policies 9
4,000,000 
Summary Of Significant Accounting Policies 10
1,000,000 
Summary Of Significant Accounting Policies 11
23,500,000 
Summary Of Significant Accounting Policies 12
171,000 
Summary Of Significant Accounting Policies 13
1,000,000 
Summary Of Significant Accounting Policies 14
308,000 
Summary Of Significant Accounting Policies 15
616,000 
Summary Of Significant Accounting Policies 16
Summary Of Significant Accounting Policies 17
1,282,000 
Summary Of Significant Accounting Policies 18
$ 1,000,000 
Summary Of Significant Accounting Policies 19
50.00% 
Leasehold Improvements and Equipment (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Leasehold Improvements And Equipment 1
$ 10 
Intangible Assets (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
M
Intangible Assets 1
$ 79 
Intangible Assets 2
$ 116 
Intangible Assets 3
100.00% 
Intangible Assets 4
39 
Deferred License Revenue (Narrative) (Details) (USD $)
12 Months Ended
Dec. 31, 2013
M
Deferred License Revenue 1
$ 1,000,000 
Deferred License Revenue 2
39 
Deferred License Revenue 3
$ 616,000 
Commitments (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
M
Y
Commitments 1
3,500 
Commitments 2
6,425 
Commitments 3
6,410 
Commitments 4
6,420 
Commitments 5
16,000 
Commitments 6
10 
Commitments 7
Commitments 8
$ 15 
Commitments 9
Commitments 10
Commitments 11
200 
Commitments 12
10.00% 
Commitments 13
$ 147 
Capital Stock (Narrative) (Details) (USD $)
12 Months Ended
Dec. 31, 2013
M
Capital Stock 1
7,900,000 
Capital Stock 2
$ 0.4419 
Capital Stock 3
7,900,000 
Capital Stock 4
$ 3,500,000 
Capital Stock 5
0.5646 
Capital Stock 6
60 
Capital Stock 7
1,808,000 
Capital Stock 8
210,000 
Capital Stock 9
6.00% 
Capital Stock 10
35,000 
Capital Stock 11
475,221 
Capital Stock 12
6.00% 
Capital Stock 13
0.5646 
Capital Stock 14
48 
Capital Stock 15
272,000 
Capital Stock 16
75,000 
Capital Stock 17
50,000 
Capital Stock 18
75,000 
Capital Stock 19
50,000 
Capital Stock 20
Capital Stock 21
Capital Stock 22
31,000 
Capital Stock 23
28,000 
Capital Stock 24
31,000 
Capital Stock 25
28,000 
Capital Stock 26
219,313 
Capital Stock 27
219,313 
Capital Stock 28
Capital Stock 29
104,000 
Capital Stock 30
104,000 
Capital Stock 31
3,098,500 
Capital Stock 32
3,098,500 
Capital Stock 33
1,000 
Capital Stock 34
1,465,000 
Capital Stock 35
1,464,000 
Capital Stock 36
1,205,668 
Capital Stock 37
491,382 
Capital Stock 38
491,382 
Capital Stock 39
Capital Stock 40
233,000 
Capital Stock 41
233,000 
Capital Stock 42
714,286 
Capital Stock 43
234,698 
Capital Stock 44
$ 0 
Income Tax (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Income Tax 1
$ 4,506 
Income Tax 2
296 
Income Tax 3
8,874 
Income Tax 4
8,390 
Income Tax 5
9,040 
Income Tax 6
8,566 
Income Tax 7
1,098 
Income Tax 8
914 
Income Tax 9
22 
Income Tax 10
212 
Income Tax 11
186 
Income Tax 12
158 
Income Tax 13
169 
Income Tax 14
232 
Income Tax 15
119 
Income Tax 16
4,354 
Income Tax 17
$ 4,464 
Related Party Transactions (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Related Party Transactions 1
$ 10 
Related Party Transactions 2
Related Party Transactions 3
39 
Related Party Transactions 4
Related Party Transactions 5
29 
Related Party Transactions 6
Related Party Transactions 7
10 
Related Party Transactions 8
23 
Related Party Transactions 9
80 
Related Party Transactions 10
$ 114 
Subsequent Events (Narrative) (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Subsequent Events 1
1,616,388 
Subsequent Events 2
1,616,388 
Subsequent Events 3
$ 0 
Subsequent Events 4
1,000,000 
Subsequent Events 5
$ 1,000,000 
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 1
20.00% 
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 2
30.00% 
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 3
$ 5 
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 4
10 
Schedule of Leasehold Improvements and Equipment (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1
$ 446 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3
446 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4
225 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5
398 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6
277 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7
121 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8
153 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9
46 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10
35 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11
11 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13
58 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14
58 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17
10 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19
10 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 21
958 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 22
370 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 23
588 
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 24
$ 387 
Schedule of Stock by Class (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Capital Stock Schedule Of Stock By Class 1
100,000,000 
Capital Stock Schedule Of Stock By Class 2
$ 0.00001 
Capital Stock Schedule Of Stock By Class 3
20,000,000 
Capital Stock Schedule Of Stock By Class 4
0.00001 
Capital Stock Schedule Of Stock By Class 5
60,984,267 
Capital Stock Schedule Of Stock By Class 6
49,890,421 
Capital Stock Schedule Of Stock By Class 7
610 
Capital Stock Schedule Of Stock By Class 8
$ 499 
Schedule of Stock Options Valuation - June13, 2012 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 1
83.00% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 2
3.1 
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 3
0.40% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - June13, 2012 4
$ 0 
Schedule of Stock Options Valuation - August 8, 2012 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 1
81.00% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 2
1.8 
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 3
0.38% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4
$ 0 
Schedule of Stock Options Valuation - December 4, 2012 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 1
78.00% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 2
3.1 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 3
0.34% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4
$ 0 
Schedule of Stock Options Valuation - December 12, 2012 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 1
70.00% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 2
1.8 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 3
0.25% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4
$ 0 
Schedule of 480,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 1
78.00% 
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 2
3.83 
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 3
0.34% 
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 4
$ 0 
Schedule of 200,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 1
77.00% 
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 2
3.13 
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 3
0.34% 
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 4
$ 0 
Schedule of 35,000 Stock Options Valuation - August 6, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 1
75.00% 
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 2
3.13 
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 3
0.62% 
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 4
$ 0 
Schedule of 75,000 Stock Options Valuation - December 3, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 1
67.00% 
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 2
3.13 
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 3
0.58% 
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 4
$ 0 
Schedule of 100,000 Stock Options Valuation - December 3, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 1
67.00% 
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 2
3.13 
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 3
0.58% 
Additional Paid-in Capital Schedule Of 1,00,000 Stock Options Valuation - December 3, 2013 4
$ 0 
Schedule of 100,000 Stock Options Valuation - December 6, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 1
67.00% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 2
3.13 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 3
0.64% 
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 6, 2013 4
$ 0 
Schedule of Stock Option Activity to Employees and Directors[Table Text Block] (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 1
$ 898,088 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 2
0.60 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 3
95,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 4
0.56 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 5
(45,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 6
(0.49)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 7
(32,500)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 8
(1.15)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 9
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 10
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 11
915,588 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 12
0.59 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 13
990,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 14
0.61 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 15
(45,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 16
(0.48)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 17
(238,088)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 18
(0.80)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 19
(25,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 20
(0.31)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 21
$ 1,597,500 
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 22
0.58 
Schedule of Stock Option Activity to Consultant's (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 1
$ 100,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 2
0.51 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 3
100,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 4
0.59 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 5
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 6
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 7
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 8
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 9
(50,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 10
(0.55)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 11
150,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 12
0.55 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 13
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 14
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 15
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 16
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 17
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 18
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 19
(50,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 20
(0.47)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 21
$ 100,000 
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 22
0.59 
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1
0.37 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2
$ 75,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3
0.07 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5
75,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7
0.45 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8
100,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9
0.08 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10
0.03 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11
100,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12
0.06 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13
0.51 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14
20,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16
0.01 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17
15,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18
0.01 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19
0.52 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21
0.07 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25
0.52 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26
275,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27
0.81 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28
0.08 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31
0.54 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32
182,500 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33
0.31 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34
0.06 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35
182,500 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36
0.14 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37
0.55 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39
0.05 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43
0.58 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44
35,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45
0.10 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46
0.01 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49
0.60 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50
55,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51
0.13 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53
27,500 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55
0.61 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56
125,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57
0.07 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59
125,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60
0.11 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61
0.62 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63
0.06 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64
0.02 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67
0.65 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68
480,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69
1.23 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 70
0.18 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 71
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 72
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 73
0.65 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 74
200,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 75
0.51 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 76
0.08 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 77
50,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 78
0.04 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 79
1,697,500 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 80
3.53 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 81
0.58 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 82
47,162 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 83
725,000 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 84
0.54 
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 85
$ 34,513 
Schedule of Warrants Valuation - December 16, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 1
80.00% 
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 2
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 3
1.55% 
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 4
$ 0 
Schedule of 0.5 million Warrants Valuation - December 16, 2013 (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Y
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 1
72.00% 
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 2
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 3
1.12% 
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 4
$ 0 
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1
$ 19,373,078 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2
0.7083 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3
(219,313)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4
(0.4700)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5
(1,205,668)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6
(0.4800)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7
(11,843,932)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8
(0.8000)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9
6,104,165 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10
0.5938 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11
7,920,346 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12
0.5646 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13
475,221 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14
0.5646 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15
(3,098,500)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16
(0.4741)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17
(257,500)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18
(0.4741)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 19
$ 11,143,732 
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 20
0.6079 
Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1
$ 278 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2
368 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3
11 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5
56 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6
18 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7
142 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8
273 
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9
(45)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10
(57)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12
$ 0 
Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1
$ 14 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2
13 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3
2,407 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4
2,278 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5
1,283 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6
1,301 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7
1,098 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8
914 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9
4,802 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10
4,506 
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11
(4,802)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12
(4,506)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14
$ 0 
Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1
$ 5 
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2
$ 3